— Why it moved
Why AIM Stock Surged Today — May 27, 2026
AIM tied its Ampligen drug to the new Ebola emergency, and a sub-dollar float ran 40%+ before giving it all back.
What moved AIM stock
AIM ImmunoTech is a beaten-down penny biotech behind Ampligen. It announced what it called an "emerging Ebola opportunity" for the drug, leaning on the WHO emergency declaration around the Bundibugyo outbreak — a preparedness pitch, not a signed deal. With Ebola names in play across biotech that day, the headline was enough to light the fuse.
The mechanics
Everything about the setup is built for a fast spike: sub-$0.50 price, a float under 8M shares, a market cap around $6M, and a topical outbreak theme. Turnover was massive relative to the company's size.
AIM by the numbers
The alert window
Stock Pulse alerted at 10:41 AM at $0.42; the peak $0.60 printed at 12:06 PM — one hour and twenty-five minutes of window, worth 44% to a real-time reader.
How AIM's move ended
The whole gain was gone by the close. It bled back through the afternoon to finish at $0.41 — basically flat, down 2% versus the alert. A textbook morning pop and afternoon give-back, on a company where Ampligen has been the perennial "next catalyst" story for years and an Ebola tie-in is speculative preparedness, not revenue. A theme headline with no signed deal behind it usually buys the morning and nothing else.